Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015
ADXS31-164 (AT-014) in Combination with Palliative Radiation Delays Tumor Progression, Prolongs Overall Survival and Maintains Limb Function in Preliminary Data from a Clinical Study in Canine Osteosarcoma
Apr 27, 2015, 09:02 ET
KANSAS CITY, Kan., April 27, 2015 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today provided commentary on clinical study data involving ADXS31-164 (AT-014) that was recently presented during a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2015.
ADXS31-164 is a novel Lm-LLO immunotherapy developed by Advaxis, Inc. (NASDAQ: ADXS) to target HER2 receptor expressing cancers. In March 2014, Aratana licensed ADXS31-164 from Advaxis for the treatment of canine osteosarcoma and other cancers, adding the drug product to its pipeline of cancer therapeutics as AT-014.
On Monday, April 20, Nicola J. Mason, BVetMed, Ph.D., DACVIM, Assistant Professor of Medicine, University of Pennsylvania's School of Veterinary Medicine, presented preliminary data from an ongoing Phase 1 clinical study of 10 companion dogs with osteosarcoma (Poster Board #7; Abstract #LB-113). The data suggests that ADXS31-164 in combination with palliative radiation delayed tumor progression and prolonged overall survival in pet dogs with spontaneous osteosarcoma that were not candidates for primary tumor removal (amputation). Repeat doses of ADXS-HER2 were well tolerated with no systemic or cardiac toxicity. Additionally, the combination treatment was found to maintain or improve limb function and quality of life over the study period. Five of the treated dogs remain alive, with a median survival, to date, of all 10 study dogs reported at 285 days, which compares favorably to historical median survival time of 136 days in dogs treated with palliative radiation only.
Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, commented, "The data presented by Dr. Mason during the AACR Annual Meeting 2015 were quite compelling and demonstrate the significant value that AT-014 offers as a potential treatment for canine osteosarcoma. We applaud Dr. Mason and her team, as well as the team at Advaxis, for the ongoing development of this important cancer immunotherapy."
About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.
Contacts:
For investor inquires:
Aratana Therapeutics, Inc.
Craig Tooman
[email protected]; (913) 353-1026
For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
[email protected]; (212) 375-2694
SOURCE Aratana Therapeutics, Inc.